PIK3C3 and melanoma: Vps34 inhibition in combination with anti-PD-1/PD-L1 immunotherapy results in reduced tumor growth and increased survival of mice with melanoma and colorectal cancer (CRC), compared with anti-PD-1/PD-L1 monotherapy treatment [166].